BIIB Q4 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.4B-6.2% YoY

Gross Profit

$1.8B74.1% margin

Operating Income

$512M21.5% margin

Net Income

$250M10.5% margin

EPS (Diluted)

$1.71

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

-$53M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$26.8B

Total Liabilities

$12.0B

Stockholders' Equity

$14.8B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.5B	-6.2%
Gross Profit	$1.8B	$2.0B	-10.4%
Operating Income	$512M	$558M	-8.2%
Net Income	$250M	$550M	-54.6%

Revenue Segments

MS Product Revenues

$1.2B43%

TYSABRI product

$465M17%

SPINRAZA

$413M15%

Fumarate

$401M15%

Interferon

$280M10%

Geographic Segments

UNITED STATES

$848M100%